TipRanks
Advertisement
Advertisement

MLTX Stock Latest News

MoonLake: Buy Rating Reaffirmed as BLA Progress, Strong HS Data Support Unchanged $34 Price Target
RatingsMoonLake: Buy Rating Reaffirmed as BLA Progress, Strong HS Data Support Unchanged $34 Price Target
18d ago
MLTX
MoonLake files FDA application for sonelokimab therapy
PremiumCompany Announcements
MoonLake files FDA application for sonelokimab therapy
22d ago
8K
MLTX
Wedbush biotech analyst holds an analyst/industry conference call
PremiumThe Fly
Wedbush biotech analyst holds an analyst/industry conference call
1M ago
MLTX
ORKA
MoonLake price target raised to $50 from $45 at H.C. Wainwright
PremiumThe Fly
MoonLake price target raised to $50 from $45 at H.C. Wainwright
2M ago
MLTX
MoonLake shares drop 11% pre-market after Q2 earnings, Phase 3 trial results
PremiumThe Fly
MoonLake shares drop 11% pre-market after Q2 earnings, Phase 3 trial results
2M ago
MLTX
MoonLake announces positive Phase 3 psoriatic arthritis results
PremiumCompany AnnouncementsMoonLake announces positive Phase 3 psoriatic arthritis results
2M ago
8K
MLTX
MoonLake Immunotherapeutics reports Q2 EPS (84c), consensus (90c)
Premium
The Fly
MoonLake Immunotherapeutics reports Q2 EPS (84c), consensus (90c)
2M ago
MLTX
MoonLake says Phase 3 IZAR-1 trial met all clinical endpoints at Week 16
Premium
The Fly
MoonLake says Phase 3 IZAR-1 trial met all clinical endpoints at Week 16
2M ago
MLTX
MLTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
MLTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
MLTX
Analyst Maintains Buy on MoonLake, Reiterates $45 Price Target on Strong Financing and Sonelokimab Commercial Potential
PremiumRatings
Analyst Maintains Buy on MoonLake, Reiterates $45 Price Target on Strong Financing and Sonelokimab Commercial Potential
3M ago
MLTX
MoonLake Immunotherapeutics Announces $200 Million Public Offering
PremiumCompany Announcements
MoonLake Immunotherapeutics Announces $200 Million Public Offering
4M ago
8K
MLTX
MoonLake Immunotherapeutics 9M share Secondary priced at $20.00
PremiumThe Fly
MoonLake Immunotherapeutics 9M share Secondary priced at $20.00
4M ago
MLTX
Buy Rating Reaffirmed on Sonelokimab’s Strong HS Data and Regulatory De-Risking; $30 Price Target Maintained
PremiumRatingsBuy Rating Reaffirmed on Sonelokimab’s Strong HS Data and Regulatory De-Risking; $30 Price Target Maintained
4M ago
MLTX
Closing Bell Movers: Avis Budget jumps over 6% on Pentwater settlement
Premium
The Fly
Closing Bell Movers: Avis Budget jumps over 6% on Pentwater settlement
4M ago
MU
CAR
MoonLake Immunotherapeutics announces $150M offering of Class A ordinary shares
Premium
The Fly
MoonLake Immunotherapeutics announces $150M offering of Class A ordinary shares
4M ago
MLTX
MoonLake Reiterated at Buy as Sonelokimab Data Underscore HS Potential; $33 Price Target Maintained
PremiumRatings
MoonLake Reiterated at Buy as Sonelokimab Data Underscore HS Potential; $33 Price Target Maintained
4M ago
MLTX
MoonLake’s SLK has ‘blockbuster potential,’ says Clear Street
PremiumThe Fly
MoonLake’s SLK has ‘blockbuster potential,’ says Clear Street
4M ago
MLTX
Buy Rating Reiterated on SLK’s Strong Phase 3 HS Data and BLA Path; $30 Price Target Maintained
PremiumRatings
Buy Rating Reiterated on SLK’s Strong Phase 3 HS Data and BLA Path; $30 Price Target Maintained
4M ago
MLTX
Midday Fly By: Chevron signs power deal with Microsoft, CRH to acquire Arcosa
PremiumThe Fly
Midday Fly By: Chevron signs power deal with Microsoft, CRH to acquire Arcosa
4M ago
MU
PR
MoonLake Highlights Strong Phase 3 Sonelokimab HS Results
PremiumCompany AnnouncementsMoonLake Highlights Strong Phase 3 Sonelokimab HS Results
4M ago
8K
MLTX
MoonLake announces Week 52 results of Phase 3 VELA-1, VELA-2 trials
Premium
The Fly
MoonLake announces Week 52 results of Phase 3 VELA-1, VELA-2 trials
4M ago
MLTX
MoonLake shareholders back director, auditor and compensation plans
Premium
Company Announcements
MoonLake shareholders back director, auditor and compensation plans
5M ago
8K
MLTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >